

## AMENDMENT

### In the Claims

The following listing of Claims replaces all prior listings, and versions, of claims in the application.

### Listing of Claims

Claims 1 – 23 (cancelled)

Claim 24. (currently amended) An isolated anti-IP-10 antibody or antigen binding fragment which binds to a the protein encoded by of SEQ ID NO: 1 ~~and, wherein said antibody or antigen binding fragment~~ comprises a heavy chain variable region comprising heavy chain CDRs complementarity determining regions (CDRs) of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 74 and a light chain variable region comprising light chain CDRs of SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 77.

Claim 25. (previously presented) The isolated anti-IP-10 antibody or antigen binding fragment of Claim 24 in which the heavy chain variable region comprises SEQ ID NO: 78.

Claim 26. (previously presented) The isolated anti-IP-10 antibody or antigen binding fragment of Claim 24 in which the light chain variable region comprises SEQ ID NO: 46.

Claim 27. (previously presented) The isolated anti-IP-10 antibody or antigen binding fragment of Claim 24 in which the heavy chain variable region comprises SEQ ID NO: 78 and the light chain variable region comprises SEQ ID NO: 46.

Claim 28. (previously presented) The isolated anti-IP-10 antibody according to Claim 24, wherein said antibody is monoclonal.

Claim 29. (previously presented) The isolated anti-IP-10 antibody according to Claim 24, wherein said antibody is a humanized antibody.

Claim 30 (previously presented): The isolated anti-IP-10 antibody according to Claim 24, wherein said antibody is a chimeric antibody.

Claim 31 (previously presented): A pharmaceutical composition comprising the isolated anti-IP-10 antibody or antigen binding fragment of Claim 24 and a physiologically acceptable pharmaceutical carrier.

Claim 32 (currently amended): A method of preventing or reducing severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof, comprising administering to said subject an effective amount of an isolated anti-IP-10 antibody or antigen binding fragment of Claim 24, wherein said antibody or antigen binding fragment blocks the binding of CXCR3 to said SEQ ID NO: 1.

Claim 33 (previously presented): The method according to Claim 32, wherein said inflammatory bowel disease is Crohn's disease.

Claim 34 (previously presented): The method according to Claim 32, further comprising administering an immunosuppressive agent to the subject.

Claim 35 (withdrawn - previously presented): The method according to Claim 32, wherein said inflammatory bowel disease is ulcerative colitis.